MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA. It has been studied as a metabolic regulator with roles in insulin sensitivity, exercise capacity, and aging-related metabolic decline. Most of the data sits in animal models, with limited human evidence.
On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 7-5 with 2 abstentions to recommend adding MOTS-c to the Section 503A Bulks List. The vote overrode FDA career-staff briefing documents (released June 29-30) that recommended against inclusion, citing thin human clinical trial evidence and 503A historical use questions. The recommendation is advisory only; FDA rulemaking to actually add MOTS-c to the bulks list takes approximately 6-18 months from the date the agency decides to act.
Before the vote, MOTS-c had become a popular research peptide in the longevity and biohacking community, sold through compounding channels and online research-peptide vendors. State medical board enforcement actions have included it. ProPublica's 2026 reporting on the FDA's 2023 effective ban listed MOTS-c among the 19 injectable peptides at issue.
Human clinical evidence remains preliminary. Stories here cover the PCAC outcome, regulatory action, and any progress toward registered trials. See [[pcac]] and [[peptide-compounding]] for adjacent threads.
Day 1 afternoon session vote tallies clarified Friday for Thursday July 23, 2026: the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 to recommend adding TB-500 (thymosin beta-4 fragment, marketed for wound healing and tissue repair) to the Section 503A Bulks List, and voted 7-5 with 2 abstentions to recommend adding MOTS-c (mitochondrial-derived peptide, nominated for obesity and metabolic disease). Both afternoon votes followed the morning session votes on BPC-157 (8-6, 1 abstention) and KPV (8-6, 1 abstention), making Thursday a clean sweep of all four Day-1 peptides. Every Day-1 win overrode the FDA career-staff briefing documents released June 29-30, which recommended against adding any of the seven peptides under review. Coverage across US News, ABC News, Bloomberg, The Hill, and Medical Daily converged on the framing that FDA career scientists were rebuked by the advisory panel on Day 1. TB-500 has been actively marketed alongside BPC-157 in 'tissue repair' and 'recovery' peptide-clinic protocols; MOTS-c has been marketed for metabolic health and mitochondrial function despite thin human clinical evidence.
The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026. Approximately 1,860 public comments have been filed on the seven-peptide review, spanning docket comments from institutional commenters supporting inclusion (Hims & Hers Health among them) and opposing inclusion (PhRMA, Partnership for Safe Medicines, American Pharmacists Association, Public Citizen, Institute for Safe Medication Practices, UC Davis's Paul Knoepfler). Hims Chief Medical Officer Dr. Anant Vinjamoori confirmed Hims will testify at Thursday's July 23 hearing at FDA's White Oak Campus in Silver Spring, Maryland. In pre-hearing remarks, Dr. Vinjamoori said medical providers should be honest about 'the relatively sparse clinical evidence for these peptides' but noted that Hims plans to offer the peptides if the FDA reclassifies them. He also cited nearly a decade of accumulated experience across 'thousands of physicians, close to millions of patients' that in his view supports the peptides' health benefits. FDA career-staff briefing documents recommend against adding any of the seven peptides to the 503A Bulks List. PCAC recommendations are advisory; FDA rulemaking (typically 6-18 months) is required before compounding pharmacies can act on any positive committee recommendation.
The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting is two days out. Written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026 (comments received via the Regulations.gov electronic filing system after that time will not be considered). The two-day meeting opens Thursday July 23 at 8:00 AM ET and closes Friday July 24 at 3:50 PM ET at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. The Washington Post reported on July 17 that FDA career staff had raised conflict-of-interest concerns ahead of the new panel composition, adding to the June 29 STAT News reporting that seven of eight new PCAC members named have documented ties to peptide-related businesses. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List. The American Pharmacists Association (APhA) filed docket comments this month urging the FDA to put patient safety first in the review.
The FDA published the final Pharmacy Compounding Advisory Committee briefing documents for the July 23-24 peptide meeting on or around Tuesday July 21, 2026, matching the agency's policy of making advisory-committee briefing documents public no later than two business days before the meeting. The seven career-staff briefing documents (one per peptide: BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, Epitalon) had already been publicly released in interim form on June 29-30, 2026 and became widely covered mainstream news through the July NPR feature, the Washington Post 'peptide showdown' Health Brief, and the STAT News reporting on panel-composition conflicts. The finalized documents formally posted to the docket recommend against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity adverse events, heavy-metal and microbial contamination in samples pulled from the compounding channel, mislabeled contents, and thin 503A historical use as the specific evidence gaps that prevent bulks-list inclusion. Publication of the final briefing documents means PCAC panelists have their complete reading package and the seven substance-specific evidence maps are the record they will deliberate against during the Thursday-Friday vote.
The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting is three days out. Written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026; the two-day meeting opens Thursday July 23 and closes Friday July 24 at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. The FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. The panel composition itself includes at least seven of eight new members named June 29 with documented ties to peptide-related businesses (per STAT News reporting). The written-comment docket has attracted filings from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices, Partnership for Safe Medicines), and academic scientists (UC Davis's Paul Knoepfler). A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting sits four days away, with the written-comment docket FDA-2025-N-6895 closing at 11:59 PM ET on Wednesday July 22, 2026. The two-day meeting opens Thursday July 23 and closes Friday July 24 at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. The written-comment docket has attracted filings from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices, Partnership for Safe Medicines), academic researchers (UC Davis's Paul Knoepfler), and individual physicians and patients across both sides. A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026, five days from today. Late submissions after Wednesday will remain on the public record but will not reach panelists before the July 23-24 meeting at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday July 23) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday July 24) reviews DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. HHS Secretary Robert F. Kennedy Jr.'s public push for expanded peptide access runs counter to the FDA career-staff recommendation, and at least seven of the eight new PCAC panelists named June 29 have ties to peptide-related businesses (per STAT News reporting). A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
The FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on seven research peptides is six days out. The written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET Wednesday July 22, one day before the meeting opens July 23-24 at White Oak. Day 1 (July 23) covers BPC-157, KPV, TB-500, and MOTS-c. Day 2 (July 24) covers DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 concluded all seven peptides have insufficient evidence for 503A bulks-list eligibility, citing immunogenicity questions, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. HHS Secretary Robert F. Kennedy Jr.'s public push for expanded peptide access runs counter to the career-staff recommendation, and at least seven of the eight new PCAC panelists named June 29 have documented ties to peptide-related businesses (per STAT News reporting). Comments filed by the July 9 member-review cutoff are already in the reading packet; comments filed between July 10 and July 22 will be on the record but reach members after their initial review. A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
The FDA Pharmacy Compounding Advisory Committee written-comment docket FDA-2025-N-6895 reaches its member-review cutoff Thursday July 9, 2026 at 11:59 PM ET. Submissions filed by this deadline go into the reading packet PCAC members review ahead of the July 23-24 meeting. Written comments filed after today remain on the public record and inform final agency deliberations but do not reach panelists before their initial preparation. The absolute hard deadline for all written comment submissions is 11:59 PM ET on Wednesday July 22, 2026, one day before the meeting opens at White Oak. The docket has attracted comments from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices), academic scientists (UC Davis's Paul Knoepfler), and individual physicians and patients on both sides. The FDA career-staff briefing documents released June 29-30 concluded all seven peptides have insufficient evidence for 503A bulks list eligibility, citing immunogenicity, heavy-metal and microbial contamination in compounded samples, mislabeled contents, and thin 503A historical use. The July 9 threshold locks in the reading pile that panelists carry into the July 23 vote.
NPR published a nationally syndicated feature Wednesday July 8, 2026 on the FDA effort to expand compounding-pharmacy access to popular peptides including TB-500, BPC-157, and MOTS-c ahead of the July 23-24 PCAC vote. The reporting placed three lines side by side: HHS Secretary Robert F. Kennedy Jr. extolled peptide benefits in a Joe Rogan interview earlier this year and promised to reverse Biden-era restrictions preventing US compounding pharmacies from making them; the Institute for Safe Medication Practices told NPR 'these peptides really do not have established effectiveness, so the only thing you have is risk'; and NPR noted many members of the FDA advisory committee have ties to the peptide industry and work for clinics that offer injectable peptides. The piece syndicated across dozens of member stations (KUAF, NSPR, WLRN, Prairie Public, HPPR, WVXU, KALW, WKNO, KUNC among them), pushing the panel-composition story past trade press (Endpoints, STAT, FiercePharma) and academic-scientist voices (Knoepfler in Washington Post) into general-audience mainstream media two weeks before the vote.
The FDA Pharmacy Compounding Advisory Committee written-comment docket FDA-2025-N-6895 reaches its first procedural cutoff Thursday July 9, 2026 at 11:59 PM ET. Comments submitted by this deadline will be formally provided to PCAC members ahead of the July 23-24 meeting. Written submissions after July 9 remain on the record but reach members after their initial review preparation. The docket's absolute hard deadline for all written comment submissions is July 22, 2026 at 11:59 PM ET (one day before the meeting opens). Compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer advocacy voices (Public Citizen), academic researchers (UC Davis's Paul Knoepfler), and individual physicians have filed comments across both the pro-approval and pro-restriction sides of the panel decision. The FDA career-staff briefing documents (released June 29-30) concluded all seven peptides have insufficient evidence for 503A bulks list eligibility, citing immunogenicity concerns, heavy-metal and microbial contamination in compounded product samples, mislabeled contents, and thin 503A historical use. The July 9 threshold is the operational moment at which panelists get their reading pile; the record they use to deliberate the July 23-24 vote is set today.
FDA career-staff scientists released their briefing documents for the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) meeting, concluding that none of the seven peptides under review (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon) has sufficient evidence to support 503A bulks list eligibility. The briefing flagged four recurring concerns: limited or inadequate safety data; characterization and impurity concerns; lack of evidence of historical use in compounding meeting bulks-list criteria; and potential immunogenicity risk based on FDA adverse event data showing immune reactions to peptide preparations. The agency also presented data on product-quality failures observed in compounding-channel preparations, including heavy-metal contamination, microbial contamination, and mislabeled contents (some vials testing well below or above the labeled peptide concentration). The conclusion directly contradicts HHS Secretary RFK Jr.'s public position that the Category 2 removals (effective April 23, 2026) were meant to clear the path for 503A bulks list addition. Coverage ran across NBC News, NPR (syndicated to KPBS, Houston Public Media, WLRN, KGOU, HPPR, STLPR), Washington Post, and STAT News. The briefing is the most substantive regulatory development on the seven peptides since the April Federal Register notice.
Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 closed at the end of business Tuesday June 30, 2026. Individuals or organizations who wanted to give a formal oral presentation at the public-comment portion of the meeting had to notify FDA by today with a brief description of the evidence or arguments to be presented, names and addresses of participants, in-person versus virtual preference, and a requested time allotment. Written comments to docket FDA-2025-N-6895 at regulations.gov remain open through July 9, 2026 for formal provision to PCAC members ahead of the meeting; the hard deadline for all written comments is July 22, 2026 at 11:59 PM ET. The two-day meeting at FDA's White Oak campus in Silver Spring, Maryland (with virtual attendance option) reviews seven peptides for 503A bulks list eligibility: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Oral-testimony filers will face the FDA career-staff briefing documents released this week concluding the evidence is insufficient on all seven substances.
Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026 closes Tuesday June 30, 2026 — one day from this Monday digest. The two-day meeting at the FDA White Oak campus in Silver Spring, Maryland (with virtual attendance option) will vote on 503A bulks list eligibility for seven peptides: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Pharmacist-facing guidance in Pharmacy Times (Annie Lambert, PharmD, BCSCP, Wolters Kluwer clinical program manager for compliance solutions, published two days ago) advised compounding pharmacies to prepare for the post-PCAC market regardless of which specific peptides receive affirmative votes. Written comments to docket FDA-2025-N-6895 remain open through July 22 at 11:59 PM ET. The seven peptides came off the FDA's Category 2 'do not compound' list effective April 23, 2026; PCAC affirmative votes plus FDA acceptance are needed for formal 503A bulks list addition. Hims & Hers (HIMS), LifeMD, Henry Meds, and the broader telehealth-peptide platform space have priced in some affirmative outcomes (Barclays $39 HIMS PT, June 17; Leerink Market Perform reiteration this past week).
The FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 at the agency's White Oak campus (Silver Spring, Maryland) reaches its first procedural cutoff next Tuesday: June 30, 2026 is the deadline to register for oral testimony in the public-comment portion of the meeting. Written comments to docket FDA-2025-N-6895 at regulations.gov must arrive by 11:59 PM ET July 22, 2026 (one day before the meeting opens). The Committee will discuss BPC-157, KPV, TB-500, and MOTS-C on Day 1 (July 23) and Emideltide/DSIP, Semax, and Epitalon on Day 2 (July 24). All seven peptides came off FDA Category 2 effective April 23, 2026. PCAC recommendations are advisory: the agency makes the final 503A bulks list decision, and the Hims & Hers (HIMS) stock breakout above $30 reflected market consensus that the July vote will tilt toward eligibility. Lengea Law and PeptideClarity have both published prescriber-facing trackers ahead of the meeting.
A 2026 Frontiers in Aging review consolidates the case for therapeutic peptides as gerontology agents, mapping mechanisms across mitochondrial-derived peptides (MOTS-c, humanin), thymic peptides (thymosin alpha-1), wound-and-tissue-repair peptides (BPC-157, TB-500), copper peptides (GHK-Cu), and growth-hormone secretagogues (CJC-1295, ipamorelin). The review frames the longevity peptide field as a clinical category that now sits alongside GLP-1 metabolic medicine — driven by Hims & Hers' 2026 longevity-specialty launch, Drexel's May 5 Q&A on peptide popularity, and the FDA Category 2 removal of 12 peptides on April 22. The piece also flags that BPC-157, TB-500, and most wellness peptides still lack published human RCTs, with clinical use largely based on case reports and preclinical mechanistic rationale.
Effective April 22, BPC-157, TB-500, Semax, Epitalon, MOTS-c and seven other peptides were formally removed from the FDA's 503A Category 2 significant-safety-concerns list after original nominators withdrew submissions. The FDA Pharmacy Compounding Advisory Committee will meet July 23-24 to decide whether to add these peptides to the 503A bulks list, which would restore legal compounding under prescription.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.